How to buy Proteostasis Therapeutics stock

Proteostasis Therapeutics, Inc is a biotechnology business based in the US. Proteostasis Therapeutics shares (PTI) are listed on the NASDAQ and all prices are listed in US Dollars. Proteostasis Therapeutics employs 44 staff and has a market cap (total outstanding shares value) of USD$2.9 million.

How to buy shares in Proteostasis Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Proteostasis Therapeutics. Find the stock by name or ticker symbol: PTI. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Proteostasis Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Proteostasis Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Proteostasis Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced investors

Webull

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active investors. We picked Webull for this category because its platform offers features that cater to advancing investors as well as beginners. The desktop app is outfitted with an extensive set of research tools, the mobile app gets high grades from users and traders can test strategies with a paper-trading feature.

What's in this guide?

1. PTI shares summary
2. Compare share dealing platforms
3. Is PTI stock a buy or sell?
4. Stock performance over time
5. Can I short PTI shares?
6. Proteostasis Therapeutics's financials
7. How volatile are PTI shares?
8. Does Proteostasis Therapeutics pay a dividend?
9. Have PTI shares ever split?
10. Other common questions

Proteostasis Therapeutics share price

Use our graph to track the performance of PTI stocks over time.

Proteostasis Therapeutics shares at a glance

• Key figures

Information last updated 2021-02-21.

52-week range	USD$17.4 - USD$37.4
50-day moving average	USD$2.6436
200-day moving average	USD$1.4018
Wall St. target price	USD$5
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.504

Buy Proteostasis Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Webull		$0	Stocks, Options, ETFs	$0	0%	Get two free stock valued between $2.50 and $250 Open an account	Margin financing rates start at 3.99%. No monthly subscription fees for margin.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Proteostasis Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Proteostasis Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting Proteostasis Therapeutics shares

There are currently 1.1 million Proteostasis Therapeutics shares held short by investors – that's known as Proteostasis Therapeutics's "short interest". This figure is 16.4% down from 1.3 million last month.

There are a few different ways that this level of interest in shorting Proteostasis Therapeutics shares can be evaluated.

Proteostasis Therapeutics's "short interest ratio" (SIR)

Proteostasis Therapeutics's "short interest ratio" (SIR) is the quantity of Proteostasis Therapeutics shares currently shorted divided by the average quantity of Proteostasis Therapeutics shares traded daily (recently around 424989.88326848). Proteostasis Therapeutics's SIR currently stands at 2.57. In other words for every 100,000 Proteostasis Therapeutics shares traded daily on the market, roughly 2570 shares are currently held short.

However Proteostasis Therapeutics's short interest can also be evaluated against the total number of Proteostasis Therapeutics shares, or, against the total number of tradable Proteostasis Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Proteostasis Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Proteostasis Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0212% of the tradable shares (for every 100,000 tradable Proteostasis Therapeutics shares, roughly 21 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Proteostasis Therapeutics.

Find out more about how you can short Proteostasis Therapeutics stock.

Have Proteostasis Therapeutics's shares ever split?

Proteostasis Therapeutics's shares were split on a 1:20 basis on 23 December 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Proteostasis Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Proteostasis Therapeutics shares which in turn could have impacted Proteostasis Therapeutics's share price.

Proteostasis Therapeutics share price volatility

Over the last 12 months, Proteostasis Therapeutics's shares have ranged in value from as little as $17.4 up to $37.4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Proteostasis Therapeutics's is 1.1167. This would suggest that Proteostasis Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Proteostasis Therapeutics overview

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

Frequently asked questions

• What percentage of Proteostasis Therapeutics is owned by insiders or institutions?

  Currently 15.299% of Proteostasis Therapeutics shares are held by insiders and 22.571% by institutions.

• How many people work for Proteostasis Therapeutics?

  Latest data suggests 44 work at Proteostasis Therapeutics.

• When does the fiscal year end for Proteostasis Therapeutics?

  Proteostasis Therapeutics's fiscal year ends in December.

• Where is Proteostasis Therapeutics based?

  Proteostasis Therapeutics's address is: 80 Guest Street, Boston, MA, United States, 02135

• What is Proteostasis Therapeutics's ISIN number?

  Proteostasis Therapeutics's international securities identification number is: US74373B1098

• What is Proteostasis Therapeutics's CUSIP number?

  Proteostasis Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74373B109